Navigation Links
Pepscan Therapeutics Presents Protein Mimicry Platform for the Discovery of anti-GPCR Antibodies at International Antibody Conference
Date:12/6/2011

SAN DIEGO, December 6, 2011 /PRNewswire/ --

Speaking today at the plenary session of the IBC's International Antibody Conference in San Diego, Dr. Klaus Schwamborn, CDO of Pepscan Therapeutics, presented Pepscan's protein mimicry platform for the discovery of therapeutic antibodies.

In his presentation 'CLIPS meets GPCRs' Dr. Schwamborn introduced the CLIPS technology and the most recent developments of immunogen design. He showed data demonstrating that Pepscan's synthetic immunogens induce potent antibodies against GPCRs and therefore are able to mimic the native receptor. Resulting antibodies do not only bind strongly to the native receptor, but also show functionality with neutralizing activity in different cell based assays. Pepscan's approach was applied to different targets, supporting the concept of a generic platform for antibody generation for any given GPCR.

Monoclonal antibody therapy is very successful and has major advantages compared to small molecule therapy. However, it is very difficult to generate monoclonal antibodies for certain important drug targets, due to technical constraints, and so far no generic approach has been documented. This is in particular valid for G-protein coupled receptors (GPCR's), for which no FDA approved antibody exists. Over the last years, Pepscan Therapeutics has validated and optimized its CLIPS technology which enables the design and synthesis of conformationally stabilized peptides with a well-defined 3D-structure, resembling the native functional protein surface. New immunogen design strategies were established which allow grafting extracellular domains of any given GPCR onto a synthetic template, mimicking the native receptor structure in an optimal way.

The platform provides a systematic and efficient way of making synthetic immunogens which induce antibodies against the native target. With these immunogens, monoclonal antibodies can be generated by using common antibody technologies, like phage display libraries or hybridoma generation procedures.

Dr. Schwamborn stated: "Our approach has proven to be successful and the fact that we have the possibility to tailor antibodies to certain GPCR domains enables us to engineer antibodies which fulfill certain biological requirements. The immunogen design concept for mimicking extracellular domains of discontinuous epitopes might be also applicable to other important target classes like ion channels".

About Pepscan Therapeutics

Pepscan Therapeutics is a privately held company based in Lelystad, The Netherlands. Pepscan is using its proprietary high throughput CLIPS protein mimicking technology for the development of novel constrained therapeutic peptides and immunogens. Besides its pipeline of proprietary anti-GPCR monoclonal antibody products, Pepscan has various ongoing collaborations with leading pharmaceutical and biotech companies to develop novel therapeutics based on the proprietary CLIPS technology.

About CLIPS

CLIPS (Chemical LInkage of Peptides onto Scaffolds) is a technology to present one or more peptides in a structurally constrained configuration. These molecules behave as functional mimics of structurally complex protein domains. CLIPS therapeutic peptides have been shown to exert improved activity and stability. CLIPS peptides are also used as superior immunogens for antibody generation against disease relevant protein targets. This is especially valuable in the case of proteins that are inaccessible as recombinant proteins, such as GPCRs.

http://www.pepscan.com 


'/>"/>
SOURCE Pepscan Therapeutics BV
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pepscan Therapeutics Strengthens Management Team
2. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
3. Echo Therapeutics Announces Pricing of $5.4 Million Registered Direct Equity Financing
4. FDA Sets April 24, 2012 as PDUFA Goal Date for Cell Therapeutics Resubmitted Pixantrone New Drug Application
5. GiiResearch.com: Polycystic Ovarian Syndrome (PCOS) Therapeutics - Market to Witness Static Growth Until 2018
6. Novelos Therapeutics Prices $5.9 Million Public Offering
7. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
8. Antiviral Therapeutics - Technologies, Markets and Companies
9. Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta
10. Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist
11. Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
Breaking Medicine News(10 mins):